Roche and Carmot Therapeutics announced a US$2.7B agreement for Roche to acquire Carmot Therapeutics, including its R&D portfolio of clinical stage incretins. The deal also provides for potential additional milestone payments of up to US$400M.
As part of the acquisition, Roche will acquire:
- CT-388, the lead asset, a Phase-2 ready, dual GLP-1/GIP receptor agonist for the treatment of obesity in patients with and without type 2 diabetes;
- CT-996, a small molecule GLP-1 receptor agonist currently in Phase-1 intended to treat obesity in patients with and without type 2 diabetes; and
- CT-868, a Phase-2, dual GLP-1/GIP receptor agonist intended for the treatment of type 1 diabetes patients with overweight or obesity.
On 9 May 2023, Roche acquired worldwide rights to Zion Pharma’s ZN-A-1041 (oral HER2 TKI).